Literature DB >> 11605079

Acute doses of d-amphetamine and bupropion increase cigarette smoking.

M S Cousins1, H M Stamat, H de Wit.   

Abstract

RATIONALE: Bupropion is used clinically as a treatment for smoking cessation, but the processes by which it reduces smoking are poorly understood. Bupropion shares some neurochemical actions and behavioral effects with the psychostimulant amphetamine, and it has been shown that amphetamine increases smoking when administered acutely. The effects of single doses of bupropion on smoking have not been studied but, based on its similarities to amphetamine, we postulated that acute bupropion would also increase smoking.
OBJECTIVE: To measure the effects of single doses of amphetamine and bupropion on smoking and craving for cigarettes in smokers.
METHODS: Cigarette smokers who were not trying to quit participated in a three-session study in which they received placebo and a single dose of either d-amphetamine sulfate (10 and 20 mg; n=10) or bupropion hydrochloride (150 and 300 mg; n=12) after overnight abstinence. The three outcome measures were: i) subjective and behavioral effects of amphetamine and bupropion after a period of acute abstinence, ii) effects of amphetamine and bupropion on subjective responses to a single, smoked cigarette, and iii) effects of the drugs on number of cigarettes smoked during an ad libitum smoking period.
RESULTS: After the acute abstinence and before smoking, both amphetamine and bupropion increased self-reported mood and euphoria, but did not change ratings of craving or withdrawal. After subjects smoked a single smoked cigarette, they reported that bupropion reduced ratings of "buzzed" and "intensity". During the period of ad libitum smoking both amphetamine and bupropion increased the number of cigarettes smoked.
CONCLUSION: Acute doses of both bupropion and amphetamine increase smoking in non-treatment-seeking smokers without altering ratings of craving or withdrawal. Bupropion reduced some of the sensory responses to the smoked cigarette. It remains to be determined why bupropion increases smoking when administered acutely under controlled conditions, while it helps to reduce smoking in patients trying to quit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605079     DOI: 10.1007/s002130100802

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

Review 1.  Medication screening for smoking cessation: a proposal for new methodologies.

Authors:  Kenneth A Perkins; Maxine Stitzer; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

Review 2.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  The sensitizing effect of acute nicotine on amphetamine-stimulated behavior and dopamine efflux requires activation of β2 subunit-containing nicotinic acetylcholine receptors and glutamate N-methyl-D-aspartate receptors.

Authors:  Myung N Kim; Emily M Jutkiewicz; Minjia Zhang; Margaret E Gnegy
Journal:  Neuropharmacology       Date:  2010-10-28       Impact factor: 5.250

4.  DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues.

Authors:  F Joseph McClernon; Kent E Hutchison; Jed E Rose; Rachel V Kozink
Journal:  Psychopharmacology (Berl)       Date:  2007-07-05       Impact factor: 4.530

5.  Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.

Authors:  Marharyta Pivavarchyk; Andrew M Smith; Zhenfa Zhang; Dejun Zhou; Xu Wang; Naoki Toyooka; Hiroshi Tsuneki; Toshiyasu Sasaoka; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

6.  Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.

Authors:  E Malcolm; F I Carroll; B Blough; M I Damaj; M Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

7.  Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money.

Authors:  Stacey C Sigmon; Jennifer W Tidey; Gary J Badger; Stephen T Higgins
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

8.  Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward.

Authors:  Tom P Freeman; Ravi K Das; Sunjeev K Kamboj; H Valerie Curran
Journal:  Soc Cogn Affect Neurosci       Date:  2014-02-12       Impact factor: 3.436

9.  Methylphenidate does not influence smoking-reinforced responding or attentional performance in adult smokers with and without attention deficit hyperactivity disorder (ADHD).

Authors:  Scott H Kollins; Erin Schoenfelder; Joseph S English; F Joseph McClernon; Rachel E Dew; Scott D Lane
Journal:  Exp Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.157

10.  Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats.

Authors:  Emily M Jutkiewicz; Danielle M Nicolazzo; Myung N Kim; Margaret E Gnegy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.